Microbot Medical

Robotics-assisted Medical Technologies

Health Tech & Life Sciences
Public on NASDAQ on Nov 2016

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees and has raised a total of $90.52 million across 15 funding rounds from 2 investors. The company achieved a significant milestone in November 2016 by initiating trading on NASDAQ as MBOT.

Business overview

Microbot Medical specializes in transformational robotic technologies, primarily focusing on the endovascular space. Its core product, the LIBERTY Robotic System, is designed as the world’s first single-use endovascular robotic system, aiming to increase access to robotic technology and revolutionize endovascular procedures. The company serves the medical devices and medical technologies sectors, with products like LIBERTY, ViRob, Self-Cleaning Shunt (SCS), TipCAT, and CardioSert.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, a critical regulatory approval that validates the system's safety and efficacy. This clearance is a strong signal to investors and the medical industry, indicating the company's readiness to advance its commercialization strategy and potentially disrupt the endovascular procedures market with its innovative robotic technology.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Microbot Medical?
In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, enabling its commercialization in the U.S. market.
What was a key commercialization step for the LIBERTY system in late 2025?
In November 2025, Microbot Medical commenced the limited market release of its LIBERTY Endovascular Robotic System in the U.S., with Emory University Hospital becoming the first institution globally to adopt the system.
What was the outcome of Microbot Medical's pivotal human clinical trial for the LIBERTY system?
In October 2024, Microbot Medical announced the successful completion of its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System, accelerating its go-to-market strategy for a commercial launch during Q2 2025.
What was a notable acquisition made by Microbot Medical in 2022?
In October 2022, Microbot Medical acquired NitiLoop, strengthening its LIBERTY Robotic System portfolio with novel FDA-cleared devices.
When did Microbot Medical become a publicly traded company?
In November 2016, Microbot Medical closed its merger transaction and initiated trading on NASDAQ as 'MBOT'.

External links